Halozyme Therapeutics (HALO) Accounts Payables (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Accounts Payables data on file, last reported at $14.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $14.1 million, down 29.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 million (down 29.77% YoY), and the FY2025 annual result was $20.9 million, up 103.91% from the prior year.
• Accounts Payables retreated to $14.1 million in Q1 2026 per HALO's latest filing, from $20.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $20.9 million in Q4 2025 and troughed at $1.3 million in Q1 2022.
• A 5-year average of $14.1 million and a median of $14.1 million in 2026 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables jumped 1048.15% in 2022, then sank 35.82% in 2024.
• A 5-year view of Accounts Payables shows it stood at $17.7 million in 2022, then plunged by 33.22% to $11.8 million in 2023, then dropped by 13.26% to $10.2 million in 2024, then jumped by 103.91% to $20.9 million in 2025, then tumbled by 32.54% to $14.1 million in 2026.
• Business Quant data shows HALO's Accounts Payables at $14.1 million in Q1 2026, $20.9 million in Q4 2025, and $15.4 million in Q3 2025.